With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.
When it comes to engaging patients and teaching them to manage their Type 1 diabetes, Sanofi is starting young. The French drugmaker last week rolled out a new app aimed at children, designed to help them share their knowledge about the disease.
Endoscopic surgery isn't usually associated with diabetes, but Fractyl Laboratories yesterday announced encouraging clinical trial results for its endoscopic procedure to treat Type 2 diabetes and revealed a $40 million Series C financing round led by investment firm Mithril Capital Management.
There's a big patient pool waiting out there for any diabetes vaccine maker that can bring a product to market, but so far, it's been a rocky road. Diamyd Medical is among the companies that have seen their share of setbacks. But after a Phase III stumble back in 2011, the EU is putting forth some cash to test its vaccine in an ongoing combination study.
Eliminating the finger-stick necessary to monitor blood glucose levels for diabetics would be a significant med tech industry accomplishment. Even the biggest corporate players are taking the challenge seriously--as witnessed by the Google partnership with Novartis last month to develop glucose monitoring contact lenses.
Back in April, Merck rolled out its America's Diabetes Challenge: Get to Your Goals campaign, aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck has a new-but-similar campaign launching, but with a tighter focus: the Hispanic community, which is disproportionately affected by the disease.
Researchers say they successfully tested in mice a molecular implant that contains gene-based mechanisms for delivering insulin based on feedback from an associated pH biosensor. By maintaining a healthy pH level between 7.35 and 7.45, the therapy, consisting of different genes and proteins, would prevent potentially fatal metabolic shock (ketoacidosis) in diabetics.
Becton, Dickinson and Company today announced that its BD AutoShield Duo pen for the delivery of insulin and diabetes drugs is now available in retail pharmacies.
Just because a drug is third to market doesn't mean it's not a viable player--especially if it has safety on its side. Just ask Biogen Idec, whose Tecfidera has quickly eclipsed its predecessors to take the multiple sclerosis market by storm. But is that type of launch in the cards for Eli Lilly and Boehringer Ingelheim's diabetes med Jardiance?
Mannkind endured a grueling 10-year battle for FDA approval of its inhaled insulin drug/device combination product, Afrezza. Now the dillema is how to sell it. The company needs to find a marketing partner fast.